TELA Bio (TELA) Common Equity (2018 - 2026)

TELA Bio has reported Common Equity for 9 years, with the latest figure at -$15.9 million in Q2 2026.

• On a quarterly basis, Common Equity fell 272.76% year-over-year to -$15.9 million in Q2 2026; TTM through Jun 2026 was -$15.9 million, a 272.76% decrease from a year earlier, with the FY2025 full-year figure at $6.3 million, down 77.82% from the prior year.
• Common Equity was -$15.9 million for Q2 2026 at TELA Bio, down from -$5.2 million in the prior quarter.
• The five-year high for Common Equity was $40.0 million in Q2 2023, with the low at -$15.9 million in Q2 2026.
• Average Common Equity over 5 years is $10.7 million, with a median of $9.6 million recorded in 2022.
• The sharpest annual moves came in 2023 and 2026: Common Equity soared 2694.36% in 2023, then plunged 272.76% in 2026.
• Over 5 years, Common Equity stood at $14.3 million in 2022, then jumped by 31.99% to $18.9 million in 2023, then surged by 50.72% to $28.5 million in 2024, then plunged by 77.82% to $6.3 million in 2025, then slumped by 351.32% to -$15.9 million in 2026.
• The last three Common Equity figures came in at -$15.9 million (Q2 2026), -$5.2 million (Q1 2026), and $6.3 million (Q4 2025), per Business Quant data.